11]. Common presentations of GBS disease in adults include skin and/or soft-tissue infection, bacteremia without focus, pneumonia, and osteomyelitis; serious clinical syndromes, such as meningitis, streptococcal toxic shock syndrome, and endocarditis, are rare but are often associated with considerable morbidity and mortality [1, 3-6, 8, 10-12] . The case fatality rate is markedly higher among adults than among neonates [1, 4-8, 10, 12, 13] .
GBS emerged rapidly in the United States during the 1970s to become the leading cause of neonatal sepsis. Several reports in recent years suggest that the incidence of GBS disease is also increasing among adults [4, 5, [7] [8] [9] [10] [13] [14] [15] . The driving force behind this change has not been fully explained, and recent trends in disease incidence have not been characterized. To date, there are no guidelines for the prevention of adult GBS disease; vaccines in development may hold promise [16, 17] .
We reviewed data from 18 years of active, population-based surveillance for invasive GBS infection in a large, multistate catchment area to characterize trends over time in the incidence of GBS disease among nonpregnant adults. We also describe the burden and epidemiology of disease in adults from 2007 to guide the development of prevention efforts.
METHODS
Population-based surveillance. Active, population-and laboratory-based surveillance for invasive GBS disease was conducted from 1 January 1990 through 31 December 2007 as part of Active Bacterial Core surveillance (ABCs), Emerging Infection Program Network, as described elsewhere [18] . The surveillance area included California ( Definitions. A case of invasive disease was defined as isolation of GBS from a normally sterile site (e.g., blood or cerebrospinal fluid) in a surveillance area resident aged у18 years who was not pregnant or р30 days postpartum on the date that a culture-positive specimen was obtained. Disease was recurrent if the case patient had у2 cultures positive for GBS that were performed у30 days apart. Nosocomial disease was defined as the isolation of GBS from a specimen from a hospitalized case patient 12 days after hospital admission. Case patients were considered to be nursing home residents if they had a long-term care facility address at the time when a culture sample was obtained.
Specimen collection and testing. [21] . Analytic methods. Disease incidence was calculated using observed case counts as numerators and using surveillance population estimates from the US Census Bureau (1990 Bureau ( -1999 or race-bridged, postcensal population estimates from the National Center for Health Statistics (2000-2007) as denominators. Because the population under surveillance expanded over time and because age and race are strongly associated with GBS incidence [3, 5, 6, 9-12, 15, 22] , we compared observed incidence for each year of analysis with (1) age-and race-adjusted incidence standardized to the US population for the corresponding year and (2) age-and race-adjusted incidence standardized to the 1990 US population. Because the 3 methods for calculating incidence yielded similar results, observed incidence is reported throughout the study. Observed incidence for consistent surveillance areas over time did not differ significantly from incidence calculated for the total area under surveillance for each year; therefore, annual observed incidence was calculated using all available data for each year. Trends over time were assessed using the x 2 linearity test and test for trend; when data were not linear, we reported the percent change in incidence or proportion. The case-fatality rate was calculated using the proportion of cases with known outcome as the denominator. Race was classified as white, black, or other; cases in patients with unknown race (226 of 1546 cases in 2007) were distributed on the basis of known racial distribution within each ABCs site and age group. Pearson's x 2 , 2-tailed Fisher's exact test, and risk ratios were used for the comparison of proportions;
and 95% confidence intervals (CIs) that P ! .05 excluded 1.0 were considered to be statistically significant. The median case patient age was 63 years (range, 18-105 years); 19.2% of case patients were aged у80 years. During the study period, the incidence of GBS disease more than doubled, increasing from 3.6 cases per 100,000 persons in 1990 to 7.3 cases per 100,000 persons in 2007 ( ). Incidence increased in P ! .001 all adult age groups; the largest increases were observed among case patients aged 65-79 years (change of 114.7% from 1990 to 2007) and among case patients aged 40-64 years (change of 92.7% from 1990 to 2007) (figure 1A). During 1990-2007, the mean difference in incidence between black and white case patients was 4.6 cases per 100,000 persons; rate differences ranged from a minimum of 3.1 cases per 100,000 persons in 1991 to a maximum of 5.8 cases per 100,000 persons in 1999 (figure 1B). The case-fatality rate decreased from 23 GBS was isolated primarily from blood (82.0%), bone (6.0%), and joint (5.4%) specimens. Polymicrobial sterile-site infections occurred in 117 (7.6%) of 1546 cases; 68.4% of such infections were in the blood, and 18.8% were in bone. The most common additional pathogens included Staphylococcus aureus (46.2%), coagulase-negative staphylococcus (12.8%), and Escherichia coli (10.3%). Polymicrobial infections occurred in 80 (6.3%) of 1268 cases of GBS bacteremia.
RESULTS

Trends
Disease presented primarily as bacteremia without focus, skin and/or soft-tissue infection, pneumonia, osteomyelitis, and joint infection (table 1) . Bacteremia without focus and pneumonia were more common among case patients aged у65 years, and osteomyelitis, skin and/or soft-tissue infection, peritonitis, meningitis, and necrotizing fasciitis were more common among young adults. A higher proportion of cases of GBS disease presented as skin and/or soft-tissue infection among case patients aged 40-64 years (29.9%) than among case patients aged 18-39 years (19.1%;
) and case patients P p .007 aged у65 years (22.6%;
). Associated osteomyelitis P p .002 was reported in 44 (11.1%) of 395 case patients with skin and/ or soft-tissue infection. Such concurrent infections were 2.5 times more likely to occur in case patients aged 40-64 years than in case patients aged у65 years (14.4% vs. 5.8%; P p ). . 009 Approximately 5% of invasive GBS cases represented recurrent GBS disease; the median time between collection of the first and second culture-positive specimens was 674 days (range, 31-4340 days). Cases of recurrent disease were significantly more likely than cases of nonrecurrent disease to present as skin and/or soft-tissue infection (43.8% vs. 24.6%; 2) . When stratified by age, serotype V was the most common serotype, except in the group of case patients aged 18-39 years. All tested isolates were susceptible to ampicillin, cefotaxime, penicillin, and vancomycin. Resistance to tetracycline, erythromycin, and clindamycin was common (83.3%, 40.0%, and 20.2%, respectively). The prevalence of resistance to levofloxicin was low (1.2%). The prevalence of erythromycin resistance was highest among serotype V isolates (56.5%). 
DISCUSSION
GBS has emerged as an important cause of invasive infection in nonpregnant adults. This multistate, population-based analysis confirms that the incidence of adult GBS disease has continued to increase, more than doubling during the 18-year study period to 7.3 cases per 100,000 persons in 2007. Consistent with previous studies, underlying medical conditions, particularly diabetes, are overrepresented among cases [3-5, 8, 10, 11, 23] . Disease rates are highest among older case patients [3, 5, 24] and black case patients [5, 9, 15] . Race may be a surrogate for other factors, such as socioeconomic status, access to health care, and underlying medical conditions, that increase the risk of disease [5, 9, 22] . Among adults aged у65 years, the incidence of GBS disease (22 cases per 100,000 persons) is 2.2 times higher than the incidence of invasive group A streptococcal disease (9.9 cases per 100,000 persons) and approaches the incidence of Streptococcus pneumoniae infection (39.3 cases per 100,000 persons) [25, 26] .
Reasons for the increasing incidence of GBS disease among nonpregnant adults are not well understood, and disease surveillance alone is not sufficient to establish the underlying cause. However, our data allowed us to exclude some hypotheses. Because the increase in incidence over time persisted when yearly incidence rates were standardized to the US population during 1990 and when adults were stratified into smaller age groups, the aging of the population is unlikely to have been the primary cause. In addition, it is unlikely that the increasing incidence was associated with the emergence or expansion of new or virulent serotypes. Serotype V, first reported in 1985 [27] , may have contributed to an increase in the incidence of disease shortly after its emergence, but it was already established in our surveillance population in 1990. Moreover, although the incidence of GBS disease has continued to increase in recent years, serotype IV was the only serotype for which the proportion increased significantly; however, this serotype accounted for only a small proportion of disease.
The increasing prevalence of adults with chronic medical conditions [4, 8, 9, 11] remains the most plausible explanation for our observed doubling in the incidence of adult GBS disease. The prevalence of diabetes (44.4%) among case patients with GBS disease is markedly higher than that in the US population (10.7% among US adults aged у20 years) [28] . In addition, the prevalences of diagnosed diabetes and obesity have more than doubled among US adults since the early 1980s [29] [30] [31] . In contrast, the incidences of cancer and cardiovascular disease, 2 other leading underlying conditions among adult case patients with GBS disease, have not increased in recent years [32, 33] . Because diabetes is a known risk factor for GBS disease among adults [3, 5, 10] , trends in the incidence of GBS disease may continue to parallel trends in the prevalence of diabetes in the US population. Additional studies are needed to further explore the association between GBS disease and key underlying medical conditions. Similarly, efforts targeting improved control and prevention of medical conditions, such as diabetes and its associated complications, might have the added benefit of reducing the risk of invasive GBS disease. Most studies of GBS disease in nonpregnant adults have reported skin and/or soft-tissue infection as the leading clinical manifestation [4] [5] [6] 11] . Because diabetes predisposes individuals to skin and soft-tissue infections, this finding may again reflect the overrepresentation of diabetes among adults with invasive GBS disease. In our study, bacteremia without focus predominated (39.3%), followed by skin and/or soft-tissue infection (25.6%). These findings were likely the result of our focus on sterile-site isolates and of the clinical limitations of chart reviews in documenting the source of GBS bacteremia. When choosing empirical therapy for the treatment of skin and soft-tissue infections, physicians should consider GBS in the differential diagnosis.
Our population-based longitudinal design provided a unique opportunity to characterize the distribution of invasive GBS serotypes in a large population over time. The observation of relative stability of serotype distribution among nonpregnant adults with invasive GBS disease over a 9-year period suggests that a GBS vaccination strategy might be feasible for prevention of GBS disease in adults. We estimated that an effective quadrivalent vaccine (including types Ia, II, III, and V) would have provided protection against 78.5% of cases of invasive GBS disease in nonpregnant adults during [2005] [2006] . Although serotype coverage is high, impaired immune responses in older adults may make vaccination a prevention strategy that is less effective in adults than it is in neonates.
There were several limitations to our study. First, because there was no control group, risk factors for disease could not be evaluated directly. Denominator data for adults in our population with key underlying conditions and by pregnancy status were not available, and clinical information collected from chart reviews was not comprehensive. The geographic area under surveillance changed during the study period; however, because restricting the analysis to consistent areas over time and standardizing results to the US population in 1990 yielded similar results, the changes in surveillance area were unlikely to have introduced important bias. Finally, GBS isolate collection was optional in the participating surveillance areas, and only a subset of areas (3 during 1998-1999 and 6 during 2005-2006) collected isolates. However, collection at participating sites remained population based, preserving representativeness of serotype distributions among the populations that did participate.
When GBS emerged as a leading cause of infection in newborns in the 1970s, intrapartum chemoprophylaxis was identified as an effective prevention strategy, and implementation led to a 180% reduction in the incidence of perinatal disease [1, 23] . The continued emergence of invasive disease among nonpregnant adults underscores the need for appropriate prevention strategies directed at this large age group. 
